Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?

被引:147
作者
Rhee, Chanu [1 ,2 ,3 ]
Kanjilal, Sanjat [1 ,2 ]
Baker, Meghan [1 ,2 ,3 ]
Klompas, Michael [1 ,2 ,3 ]
机构
[1] Harvard Med Sch, Dept Populat Med, Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA
[2] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Infect Control Dept, 75 Francis St, Boston, MA 02115 USA
基金
美国医疗保健研究与质量局;
关键词
SARS-CoV-2; COVID-19; transmission-based precautions; isolation; CLINICAL CHARACTERISTICS;
D O I
10.1093/cid/ciaa1249
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Defining the duration of infectivity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has major implications for public health and infection control practice in healthcare facilities. Early in the pandemic, most hospitals required 2 negative RT-PCR tests before discontinuing isolation in patients with Covid-19. Many patients, however, have persistently positive RT-PCR tests for weeks to months following clinical recovery, and multiple studies now indicate that these generally do not reflect replication-competent virus. SARS-CoV-2 appears to be most contagious around the time of symptom onset, and infectivity rapidly decreases thereafter to near-zero after about 10 days in mild-moderately ill patients and 15 days in severely-critically ill and immunocompromised patients. The longest interval associated with replication-competent virus thus far is 20 days from symptom onset. This review summarizes evidence-to-date on the duration of infectivity of SARS-CoV-2, and how this has informed evolving public health recommendations on when it is safe to discontinue isolation precautions.
引用
收藏
页码:1467 / 1474
页数:8
相关论文
共 64 条
[1]  
Agarwal V, 2020, QUANTIFYING PREVALEN
[2]   SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication [J].
Alexandersen, Soren ;
Chamings, Anthony ;
Bhatta, Tarka Raj .
NATURE COMMUNICATIONS, 2020, 11 (01)
[3]  
Amanat F, 2020, NAT MED, V26, P1033, DOI [10.1101/2020.03.17.20037713, 10.1038/s41591-020-0913-5]
[4]   Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance [J].
不详 .
PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE, 2020, 16 (01) :9-26
[5]  
[Anonymous], SYMPT BAS STRAT DISC
[6]  
[Anonymous], 2020, NEW ENGL J MED, DOI DOI 10.1056/NEJMOA2001316
[7]   Presumed Asymptomatic Carrier Transmission of COVID-19 [J].
Bai, Yan ;
Yao, Lingsheng ;
Wei, Tao ;
Tian, Fei ;
Jin, Dong-Yan ;
Chen, Lijuan ;
Wang, Meiyun .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (14) :1406-1407
[8]   Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples [J].
Bullard, Jared ;
Dust, Kerry ;
Funk, Duane ;
Strong, James E. ;
Alexander, David ;
Garnett, Lauren ;
Boodman, Carl ;
Bello, Alexander ;
Hedley, Adam ;
Schiffman, Zachary ;
Doan, Kaylie ;
Bastien, Nathalie ;
Li, Yan ;
Van Caeseele, Paul G. ;
Poliquin, Guillaume .
CLINICAL INFECTIOUS DISEASES, 2020, 71 (10) :2663-2666
[9]   Time lines of infection and disease in human influenza: A review of volunteer challenge studies [J].
Carrat, Fabrice ;
Vergu, Elisabeta ;
Ferguson, Neil M. ;
Lemaitre, Magali ;
Cauchemez, Simon ;
Leach, Steve ;
Valleron, Alain-Jacques .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2008, 167 (07) :775-785
[10]  
Centers for Disease Control and Prevention, DISC TRANSM BAS PREC